Nutrients Study Finds GingerT3® Reduces Joint Pain, Improves Function, and Lowers Inflammation in Adults

Tysons Corner, VA (August 12, 2025) — A newly published clinical trial in Nutrients (July 2025, Volume 17) found that GingerT3®, Specnova’s proprietary, fermented, high-potency ginger extract, significantly improved perceptions of pain, functional capacity, and inflammatory markers in adults experiencing mild to moderate muscle and joint pain. Key findings included:

• Significant reduction in muscle pain
• Improvements in self‑reported pain, stiffness, and functional capacity
• Reductions in inflammatory markers such as IL‑6, IFN‑γ, TNF‑α, and C‑reactive protein

The research was completed in partnership with the Exercise & Sport Nutrition Laboratory at Texas A&M University and Increnovo LLC.

In this randomized, double‑blind, placebo‑controlled study, 30 men and women (average age ~56 years) with a history of mild to severe joint and muscle pain as well as inflammation were randomized to receive 125 mg/day of GingerT3 (standardized to 10% total gingerols, ≤ 3 % shogaols) or a placebo for 58 days.

Participants completed pain and range of motion and flexibility assessments at baseline, Day 30, and Day 56 of supplementation. After two days of recovery from exercise challenges (squats and deep knee-bends), they were reassessed. Participants also completed a food log.

Participants found:

• Less Pain From Sitting (WOMAC Subscale) – At 48 hours post-exercise, the ginger group reported significantly less pain (p<0.05)
• Lequesne Questionnaire (Nocturnal Pain & Stairs) – Participants reported less pain during nocturnal bed rest and stair use (p<0.05)

According to Specnova founder and CEO Sebastian Balcombe, MS, “GingerT3 is the only fast‑acting, low dose ginger extract available with this unique compositional profile. It delivers statistically significant improvements in joint comfort and anti‑inflammatory benefits with an exceptionally small 125mg a day dose.” Drawing on proprietary processes, GingerT3 first uses supercritical CO₂ extraction methods to extract and concentrate the gingerols out of the ginger oil. This is followed by fermentation of the non‑oleoresin portions of the ginger rhizome which increases stability. These proprietary processes allow GingerT3® to be more stable while concentrating gingerols, shogaols, paradols, gingerdiones, and terpenes; compound classes shown to inhibit TRPV1, 5‑LOX, and COX‑2 pathways involved in pain and inflammation. “These proprietary processes give us the highest possible gingerol content while still maintaining a flowable powder, ultimately allowing GingetT3® to perform better than other ginger extracts in the market, as our now published clinical study supports,” says Balcombe.

For more information, visit specnova.com/gingert3

Media contact:
Scott Berg, Marketing Manager
sberg@specnova.com